Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Christina Marchand"'
Publikováno v:
Renewable and Sustainable Energy Transition, Vol 3, Iss , Pp 100046- (2023)
Energy scenarios are often claimed to support decision-makers involved in the energy transition. However, an empirical understanding of how decision makers select, interpret, and use energy scenarios is largely missing. This study examined how high-l
Externí odkaz:
https://doaj.org/article/0c484501454a48578406ef5dc524c910
Publikováno v:
Phosphorus, Sulfur, and Silicon and the Related Elements. 136:287-290
Autor:
Maha Hassan, Laura Sevick, Amanda S. Manoharan, Chanele Polenz, Christina Marchand, Ronald Burkes, Christine Brezden Masley
Publikováno v:
Chemotherapy: Open Access.
Publikováno v:
Annals of Oncology. 24:iv101
Autor:
Amanda S. Manoharan, Maha Hassan, Christina Marchand, Christine B. Brezden, Chanele Polenz, Ronald Burkes, Laura Sevick
Publikováno v:
Journal of Clinical Oncology. 31:e17557-e17557
e17557 Background: Optimal treatment of patients with colorectal cancer (CRC) includes the timely administration of adjuvant chemotherapy (AC). While Cancer Care Ontario (CCO) guidelines advise that CRC patients receive their first AC no later than 8
Autor:
Laura Sevick, Christina Marchand, Maha Awaiz Hassan, Rosane Nisenbaum, Delilah Lisa Topic, Audrey Wong, Sophie Hogeveen, Ata Ansari, Christine Brezden-Masley, Jalal Ebrahim, Ammar Bookwala
Publikováno v:
Journal of Clinical Oncology. 31:527-527
527 Background: Cancer Care Ontario (CCO) guidelines advise that colorectal cancer (CRC) patients receive their first adjuvant chemotherapy (AC) no later than 8 weeks after surgical resection, with new data suggesting optimal treatment to commence be
Autor:
Ammar Bookwala, Daisy Dastur, Ata Ansari, Jalal Ebrahim, Audrey Wong, Christina Marchand, Christine B. Brezden, Sophie Hogeveen, Laura Sevick
Publikováno v:
Journal of Clinical Oncology. 30:36-36
36 Background: The medical specialty of oncology relies heavily on clinical trials to advance policies and practices related to cancer care. However, oncology clinical trial accrual in Ontario has dropped from 12.4% in 2007, to 8.5% in 2009. The obje